Keep pulling the thread on Daniel Payne.
President Trump signed a new executive order concerning psychedelic treatment research and access.
An executive order on psychedelics calls on the FDA to accelerate the approval process for some of these drugs.
The executive order directs the Department of Justice and the DEA to review the scheduling of psychedelic drugs following successful Phase 3 trials.
A 2024 Stanford University study published in Nature Medicine found that the psychedelic drug Ibogaine was helpful for injured soldiers.
In a Stanford University study, 30 U.S. Special Ops veterans with traumatic brain injuries experienced average symptom reductions of 88% for PTSD, 87% for depression, and 81% for anxiety after receiving Ibogaine treatment.
The psychedelic drug Ibogaine has well-documented cardiac risks.
Nora Volkov stated at a 2024 STAT event that Ibogaine is unlikely to ever receive FDA approval due to its cardiac toxicity.
Ross Ellenhorn and Demetri Mugianis assert that the "Big Beautiful Bill" will cut more than $1 trillion from federal programs that fund addiction treatment and mental health care.
Joe Rogan had previously sent a message to President Trump encouraging him to investigate research on the psychedelic drug Ibogaine.
The executive order on psychedelics expands access to new patient populations through the Right to Try Act.
The executive order allocates funding to states, from money previously appropriated to HHS, to advance research and clinical use of psychedelic drugs.
NIH Director Jay Bhattacharya stated during the executive order announcement that it is important to ensure the scientific rigor of psychedelic research.